Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluocortolone caproate is a synthetic glucocorticoid corticosteroid used primarily for its anti-inflammatory and immunosuppressive effects. It is indicated for the topical treatment of hemorrhoids, anal fissures, proctitis, and corticosteroid-responsive dermatoses. The drug acts as an agonist of the glucocorticoid receptor (NR3C1), leading to suppression of inflammatory gene expression and reduction in the production of inflammatory mediators such as cytokines and chemokines. Fluocortolone caproate is often formulated as suppositories or ointments for rectal or topical use. It may be used alone or in combination with other agents such as local anesthetics (e.g., cinchocaine) or other corticosteroids (e.g., fluocortolone pivalate). The compound has been marketed since at least 1969[1][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluocortolone caproate.